Meta-Analysis Compared Cisplatin and Carboplatin Efficacy
Researchers analyzed over 12,000 patient cases to evaluate treatment differences across seven major cancer types.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Do you trust that your medical treatments are based on the latest scientific evidence?
An umbrella meta-analysis published in 2026 synthesized data from 52 original studies to compare the efficacy and safety profiles of cisplatin and carboplatin. The study examined outcomes for patients across seven tumor groups, including lung, ovarian, and urothelial cancers.
Why it matters
The analysis sought to provide clinical clarity on the comparative performance of these two common chemotherapy agents. By synthesizing extensive existing evidence, the study highlights critical differences in toxicity profiles and response rates that inform treatment selection.
The study integrated data from 12,683 patients across 52 trials, identifying a 38% higher objective response rate for cisplatin in advanced urothelial carcinoma. However, many tumor types and specific patient outcomes still lack high-certainty evidence.
The players
JAMA Network Open
This is a peer-reviewed, open-access medical journal that publishes clinical research and policy papers.
The details
Researchers used the GRADE system to assess the certainty of evidence regarding survival and response outcomes for seven major tumor groups. While cisplatin showed superior response rates in urothelial cancer, progression-free survival rates in advanced ovarian cancer showed no statistically significant difference between the two treatments.
Timeline
The umbrella meta-analysis was published in 2026.
The Big Picture
This study utilizes the GRADE system to standardize how clinical findings are weighed in oncology. It marks a critical step in reconciling decades of trial data to determine which chemotherapy regimens offer the most predictable clinical outcomes.
Patients may experience different side effect profiles depending on whether their regimen is based on cisplatin or carboplatin. Discussions with oncologists regarding kidney, hearing, and hematologic toxicity risks are essential for patients navigating these specific chemotherapy options.
The takeaway
Understanding the distinct toxicity profiles of cisplatin and carboplatin is vital for personalizing cancer treatment plans. Patients should consult their care teams to evaluate how the evidence-based findings align with their specific diagnosis and health goals.
Further reading
Learn more about evolving treatment standards in our Cancer section.
More information
Review the full findings in the JAMA Network Open study.
Source note: This article includes information reported by Biotech-spain.
Live Poll
Do you trust that your medical treatments are based on the latest scientific evidence?
